Anti-Müllerian Hormone (ovarian reserve — BSO timing in BRCA carriers)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-AMH-OVARIAN-RESERVE |
|---|---|
| Type | Biomarker |
| Aliases | AMHAnti-Müllerian HormoneMISMüllerian inhibiting substanceАнтимюллерів гормон (оваріальний резерв — час BSO у носіїв BRCA) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | DIS-OVARIAN |
| Sources | SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025 |
Biomarker Facts
| Biomarker type | serum_marker |
|---|---|
| Measurement | MethodSerum immunoassay (ECLIA, CLIA); cycle-day-independent Unitsng/mL (or pmol/L; conversion 1 ng/mL ≈ 7.14 pmol/L) Typical range
|
| Related biomarkers | None declared |
Notes
Granulosa-cell-derived hormone reflecting primordial follicle pool; best single biomarker of ovarian reserve. Adjunct to risk-reducing bilateral salpingo-oophorectomy (RRSO) counseling in BRCA1/BRCA2 germline carriers and other HBOC syndromes (BRIP1, RAD51C, RAD51D, PALB2). NCCN 2025 (Genetic/Familial High-Risk: Breast/Ovarian): BRCA1 RRSO recommended at age 35-40 (after completion of childbearing); BRCA2 at age 40-45. AMH supports timing discussion — declining AMH (<1.0 ng/mL = diminished reserve) helps quantify remaining reproductive window and informs fertility-preservation referral (oocyte/embryo cryopreservation) before RRSO. NOT a screening test for ovarian cancer (CA-125 + TVUS combination has been evaluated and is NOT recommended for screening per UKCTOCS — no mortality benefit). Used in pediatric ovarian function monitoring after gonadotoxic chemotherapy (childhood cancer survivors). Falsely elevated in granulosa-cell tumors and PCOS; falsely suppressed by hormonal contraceptives. STUB pending two-Co-Lead signoff.
Used By
Actionability
BMA-AMH-OVARIAN-RESERVE-BSO-TIMING- Anti-Müllerian Hormone (AMH) reflects primordial follicle pool size and is the best singl...